Advertisement

Topics

Alcresta Pharmaceuticals, Inc. Company Profile

09:50 EST 15th December 2018 | BioPortfolio

Alcresta is a specialty pharmaceutical company dedicated to developing and commercializing novel enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency, which results in malabsorption common in cystic fibrosis, digestive cancers, premature birth and other serious diseases. The company’s lead product, Relizorb™, is designed to reliably and efficiently deliver the optimal nutritional and caloric benefit from existing enteral tube feeding formulas by improving the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). The importance of long-chain polyunsaturated fatty acids like omega-3 is well documented across the full spectrum of patient care from infants to adults and individuals battling acute conditions or chronic diseases. The company’s platform is supported by the Alcresta team’s extensive experience in pharmaceutical and nutritional product development. Based in Newton, Mass., the company is backed by top-tier venture investors Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures. For more information, please visit www.alcresta.com.


News Articles [319 Associated News Articles listed on BioPortfolio]

Alcresta Therapeutics Announces RELiZORB® iMMOBILIZED LIPASE CARTRIDGE has been Issued a Unique Q-Code (Q9994) by CMS

Alcresta Therapeutics, Inc. today announced the issuance of a unique Q-code by CMS for its digestive enzyme cartridge RELiZORB. RELiZORB (iMMOBILIZED LIPASE) CARTRIDGE is an in-li...

Alcresta Therapeutics Announces RELiZORB® iMMOBILIZED LIPASE CARTRIDGE has been Issued a ...

Read more...

Alcresta Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 17092018] Prices from USD $250

SummaryAlcresta Therapeutics Inc Alcresta develops and commercializes enzymebased products for the treatment of gastrointestinal disorders and rare diseases. The company's proprietary technology platf...

Alcresta Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12042018] Prices from USD $250

SummaryAlcresta Therapeutics Inc Alcresta develops and commercializes enzymebased products for the treatment of gastrointestinal disorders and rare diseases. The company's proprietary technology platf...

AMAG Pharmaceuticals to Acquire Perosphere Pharmaceuticals

AMAG Pharmaceuticals said today it has agreed to acquire Perosphere Pharmaceuticals for up to $415 million, in a deal that the buyer said will expand its pipeline, and especially its presence in hemat...

Deals and M&As this week: Aridis Pharmaceuticals, Xeris Pharmaceuticals, Astellas Pharma

Aridis Pharmaceuticals has raised $26m through an initial public offering of two million shares of its common stock priced at $13...Read More... The post Deals and M&As this week: Aridis Pharmac...

Data from the ASSURE Study of Long-Term Use of RELiZORB® Published in Journal of Pediatric Gastroenterology and Nutrition

Largest Prospective Trial of Enteral Feeding in Cystic Fibrosis Shows Sustained Use of RELiZORB Can Help Hydrolyze Fatty Acids and Normalize Absorption Alcresta Therape...

GW Pharmaceuticals plc: GW Pharmaceuticals presents latest cannabidiol oral solution (CBD) data at the 13th European Congress of Epileptology

VIENNA, Austria, Aug. 28, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the development and commercialization of cannabinoid prescr...

Drugs and Medications [270 Associated Drugs and Medications listed on BioPortfolio]

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

Eyewash station additive concentrate [Niagara Pharmaceuticals Inc.]

EYEWASH STATION ADDITIVE CONCENTRATE

PubMed Articles [129 Associated PubMed Articles listed on BioPortfolio]

Swimming activity in zebrafish larvae exposed to veterinary antiparasitic pharmaceuticals.

Veterinary antiparasitic pharmaceuticals have been detected in surface waters and several of these pharmaceuticals act on the nervous system on the target organisms implying that neurological effects ...

Chiral pharmaceuticals: Environment sources, potential human health impacts, remediation technologies and future perspective.

Chiral pharmaceuticals (CPs), including non-steroid anti-inflammatory drugs (NSAIDs), β-blockers and some herbicide and pesticides, are widely used in aquaculture, clinical treatment and many other f...

Assessment of 83 pharmaceuticals in WWTP influent and effluent samples by UHPLC-MS/MS: Hourly variation.

The removal efficiency of pharmaceuticals in wastewater treatment plants (WWTPs) is variable and some of these compounds pass these plants almost intact and others presenting a removal efficiency clos...

Effects of pharmaceuticals on microbial communities and activity of soil enzymes in mesocosm-scale constructed wetlands.

Cyperus alternifolius based mesocosm-scale constructed wetland was employed to remove pharmaceuticals. We investigated the microbial community composition using phosphor lipid fatty acids (PFLAs) anal...

Impact of Pharmaceuticals on the Environment: Risk Assessment Using QSAR Modeling Approach.

An extensive use of pharmaceuticals and the widespread practices of their erroneous disposal measures have made these products contaminants of emerging concern (CEC). Especially, active pharmaceutical...

Clinical Trials [228 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Companies [1344 Associated Companies listed on BioPortfolio]

Alcresta Therapeutics, Inc.

Alcresta Therapeutics, Inc. is dedicated to developing and commercializing novel enzyme-based products designed to treat gastrointestinal disorders and rare diseases. The company ...

Alcresta Pharmaceuticals, Inc.

Alcresta is a specialty pharmaceutical company dedicated to developing and commercializing novel enzyme-based products designed to address challenges faced by people living with g...

Alcresta

Alcresta is developing and commercializing innovative enzyme-based nutritional products that improve patient health and manage disease for infants, adults and patients battling ac...

Alcresta, Inc.

Alcresta is a leading medical nutrition company developing and commercializing innovative enzyme-based products to improve the digestion and absorption of key nutrients to support...

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

More Information about "Alcresta Pharmaceuticals, Inc." on BioPortfolio

We have published hundreds of Alcresta Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Alcresta Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Alcresta Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alcresta Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Alcresta Pharmaceuticals, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record